Antimicrobial Resistance Diagnostic Market
Antimicrobial Resistance Diagnostic Market Forecasts to 2030 - Global Analysis By Pathogen (Drug Resistant Streptococcus, Drug Resistant Streptococcus Pneumoniae (DRSP), Methicillin Resistant Staphylococcus Aureus, Clostridium Difficile (CD), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS) and Other Pathogens), Technology, End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $4.76 BN |
|
Projected Year Value (2030) |
US $9.58 BN |
|
CAGR (2023 - 2030) |
10.5% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Antimicrobial Resistance Diagnostic Market is accounted for $4.76 billion in 2023 and is expected to reach $9.58 billion by 2030 growing at a CAGR of 10.5% during the forecast period. The market for diagnostic tests and instruments used to find and establish the presence of antimicrobial resistance (AMR) in microorganisms is referred to as the "antimicrobial resistance diagnostic market." As a result of the development of the ability of microorganisms, including bacteria, viruses, fungi, and parasites, to withstand the effects of antimicrobial medications, which reduces or eliminates their effectiveness in treating infections, antimicrobial resistance is a major public health concern worldwide.
According to the United States Pharmacopeial Convention, AMR caused about 700,000 deaths globally every year. Moreover, the number can reach 10 million each year by 2050, if diagnosis and treatment of microbial infections are not managed properly.
Market Dynamics:
Driver:
Increasing initiatives and awareness
Increased initiatives aimed at combating the problem were made possible by the growing knowledge of the effects of antibiotic resistance among healthcare professionals, legislators, and the general public. Furthermore, governments, organizations, and regulatory authorities have started campaigns to encourage the responsible use of antibiotics as well as the creation and acceptance of diagnostic tools to combat resistance.
Restraint:
Expensive diagnostic procedures and policies for limited reimbursement
Some cutting-edge antimicrobial resistance diagnostic tests can be expensive, which restricts access to and use of them, particularly in places with low resources. The high price of diagnostic tests may be an obstacle to market expansion, especially in areas with constrained healthcare resources. However, antimicrobial resistance diagnostics may be covered and reimbursed under different policies, depending on the region and healthcare system. Their uptake and market expansion may be hampered by inadequate payment or a lack of insurance coverage for certain tests.
Opportunity:
Technological developments and guidelines and support for regulations
Diagnostic technology advancements in areas like molecular diagnostics and next-generation sequencing have improved the capability of tests for antibiotic resistance. These innovations allow for the quicker and more precise detection of resistance markers, empowering medical professionals to determine effective treatments. Additionally, the importance of antibiotic resistance has been acknowledged by regulatory bodies and healthcare organizations, which have released recommendations and guidelines to promote their usage. These regulations support the regulatory environment needed for market expansion while facilitating the uptake of diagnostics.
Threat:
Inadequate infrastructure and expertise and complex regulatory procedures
Antimicrobial resistance tests may not be used to their full potential in some areas due to a lack of knowledge about them. Inadequate healthcare infrastructure and a lack of laboratory space might also prevent the use of modern diagnostics and restrain market expansion. However, it might take a while and be difficult to get regulatory approval for novel diagnostic tests for antibiotic resistance. The introduction of novel diagnostics might be hampered by strict regulatory regulations, which can often delay the launch of products.
Covid-19 Impact:
Priorities in healthcare have dramatically changed as a result of the COVID-19 pandemic to focus on managing and containing the virus's spread. Resources have been redirected toward COVID-19 testing and treatment, including laboratory capacity and manpower. The concentration on antimicrobial resistance diagnostics and research efforts in this area may have been momentarily hampered by this resource relocation. Due to the possibility of secondary bacterial infections in COVID-19 patients, the COVID-19 pandemic has resulted in an increase in the use of antibiotics.
The methicillin resistant staphylococcus aureus segment is expected to be the largest during the forecast period
Methicillin Resistant Staphylococcus Aureus segment commanded the largest share over the forecast period. The main cause of the segment's growth is the rising prevalence of MRSA in hospital settings. For instance, the CDC reports that approximately two in every 100 of those with S. aureus on their noses develop MRSA. This percentage of the population is roughly 33%. Moreover, another element influencing the segment's growth is the rise in regulatory approvals for diagnostic tests for identifying MRSA.
The hospitals segment is expected to have the highest CAGR during the forecast period
Because of the rising rate of hospital-acquired infections, the surge in hospitalizations caused by the high rate of AMR infections, prolonged hospital stays, expanding access to cutting-edge diagnostic technologies, affordability, and better healthcare coverage, the hospital segment is predicted to grow profitably over the forecast period. Additionally, pathogenic infections, including MRSA, CDI, and DRSP, can result in pneumonia, sepsis, bloodstream infections, and surgical site infections. Therefore, the prevalence of pathogen-focused illnesses in hospitals also contributes to segment growth.
Region with largest share:
Due to the high risk of developing AMR, the presence of supportive government AMR regulations, and the region's advanced healthcare infrastructure, North America held the largest percentage over the predicted period. Furthermore, it is anticipated that regional expansion will be fueled in the upcoming years by the existence of major market participants and the strategic initiatives.
Region with highest CAGR:
During the forecast period, Asia-Pacific is expected to experience the most rapid expansion. A high frequency of antibiotic resistance, an increase in the demand for affordable diagnostic solutions, and the presence of unexplored market potential all contribute to the region's growth. Additionally, the region's expansion is also anticipated to be aided by the region's sizable, targeted population, growing geriatric population, and a number of government-sponsored awareness campaigns. Additionally, it is anticipated that growth in R&D efforts connected to the creation of improved diagnostic solutions will support region expansion.
Key players in the market
Some of the key players in Antimicrobial Resistance Diagnostic market include Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux , Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Molsid , OpGen, Vela Diagnostics and Visby Medical, Inc.
Key Developments:
In November 2022, Danaher Corporation came into partnership with Duke University, a research University. Under this partnership, Danaher Corporation aimed to shape Danaher Beacon for the development of Gene Therapy Innovation.
In August 2022, Becton, Dickinson, and Company entered into collaboration with Accelerate Diagnostics, Inc., a developer of rapid in-vitro diagnostics in microbiology. This Collaboration would enable the former company to help clinicians treat patients in a Constructive and organized way resulting in a decrease in costs in healthcare and helping restrict the stretch of antimicrobial resistance.
Pathogens Covered:
• Drug Resistant Streptococcus
• Drug Resistant Streptococcus Pneumoniae (DRSP)
• Methicillin Resistant Staphylococcus Aureus
• Clostridium Difficile (CD)
• Drug Resistant Neisseria Gonorrhoeae (DRNG)
• Drug Resistant Salmonella (DRNTS)
• Other Pathogens
Technologies Covered:
• Immunoassay
• Microbiology Culture
• Mass Spectrometry
• Rapid & Point of Care
• Other Technologies
End Users Covered:
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Hospitals
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Antimicrobial Resistance Diagnostic Market, By Pathogen
5.1 Introduction
5.2 Drug Resistant Streptococcus
5.3 Drug Resistant Streptococcus Pneumoniae (DRSP)
5.4 Methicillin Resistant Staphylococcus Aureus
5.5 Clostridium Difficile (CD)
5.6 Drug Resistant Neisseria Gonorrhoeae (DRNG)
5.7 Drug Resistant Salmonella (DRNTS)
5.8 Other Pathogens
6 Global Antimicrobial Resistance Diagnostic Market, By Technology
6.1 Introduction
6.2 Immunoassay
6.3 Microbiology Culture
6.4 Mass Spectrometry
6.5 Rapid & Point of Care
6.6 Other Technologies
7 Global Antimicrobial Resistance Diagnostic Market, By End User
7.1 Introduction
7.2 Pharmaceutical & Biotechnology Companies
7.3 Diagnostic Laboratories
7.4 Hospitals
7.5 Other End Users
8 Global Antimicrobial Resistance Diagnostic Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Abbott Laboratories
10.2 Accelerate Diagnostics, Inc.
10.3 Becton, Dickinson and Company
10.4 Biomerieux
10.5 Danaher Corporation
10.6 F. Hoffmann-La Roche Ltd.
10.7 Hologic, Inc.
10.8 Molsid
10.9 OpGen
10.10 Vela Diagnostics
10.11 Visby Medical, Inc.
List of Tables
1 Global Antimicrobial Resistance Diagnostic Market Outlook, By Region (2021-2030) ($MN)
2 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
3 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
4 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
5 Global Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
6 Global Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
7 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
8 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
9 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
10 Global Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
11 Global Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
12 Global Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
13 Global Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
14 Global Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
15 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
16 Global Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
17 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
18 Global Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
19 Global Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
20 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
21 North America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
22 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
23 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
24 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
25 North America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
26 North America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
27 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
28 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
29 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
30 North America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
31 North America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
32 North America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
33 North America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
34 North America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
35 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
36 North America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
37 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
38 North America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
39 North America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
40 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
41 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
42 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
43 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
44 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
45 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
46 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
47 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
48 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
49 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
50 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
51 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
52 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
53 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
54 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
55 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
56 Europe Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
57 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
58 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
59 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
60 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
61 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
62 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
63 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
64 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
65 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
66 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
67 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
68 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
69 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
70 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
71 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
72 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
73 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
74 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
75 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
76 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
77 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
78 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
79 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
80 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
81 South America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
82 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
83 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
84 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
85 South America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
86 South America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
87 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
88 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
89 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
90 South America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
91 South America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
92 South America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
93 South America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
94 South America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
95 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
96 South America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
97 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
98 South America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
99 South America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
100 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
101 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
102 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
103 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
104 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
105 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
106 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
107 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
108 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
109 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
110 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
111 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
112 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
113 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
114 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
115 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
116 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
117 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
118 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
119 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
120 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
List of Figures
Figure 1 Global Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 2 North America Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 3 US Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 4 Canada Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 5 Mexico Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 6 Europe Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 7 Germany Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 8 UK Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 9 Italy Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 10 France Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 11 Spain Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 12 Rest of Europe Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 13 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 14 Japan Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 15 China Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 16 India Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 17 Australia Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 18 New Zealand Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 19 South Korea Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 20 Rest of Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 21 South America Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 22 Argentina Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 23 Brazil Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 24 Chile Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 25 Rest of South America Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 26 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 27 Saudi Arabia Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 28 UAE Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 29 Qatar Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 30 South Africa Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
Figure 31 Rest of Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook (2021-2030) ($MN)
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
